OSCR
Oscar Health, Inc.
OSCR has the edge over XRAY overall, supported by stronger fundamentals and stronger modeled upside.
XRAY
DENTSPLY SIRONA Inc.
XRAY has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XRAY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
XRAY's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XRAY PE Valuation
XRAY has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over XRAY on the outlook, with more favorable earnings and revenue expectations.
XRAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect XRAY's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XRAY on earnings quality, reporting a profit while its opponent remains loss making.
XRAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.26 | — |
| Q3 2026 | -$0.62 | +$3.73 |
| Q2 2026 | -$2.75 | +$1.92 |
| Q1 2026 | -$3.15 | +$1.32 |
| Q4 2025 | -$3.00 | +$1.48 |
| Q3 2025 | -$4.35 | -$2.28 |
| Q2 2025 | -$4.67 | -$3.81 |
| Q1 2025 | -$4.47 | -$4.03 |
| Q4 2024 | -$4.48 | -$3.86 |
XRAY is still losing money, but far less than before: $0.62 per share over the past year, against $4.82 at its worst in early 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XRAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
XRAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $836M | -7.5% |
| Q2 2026 | $898M | -4.1% |
| Q1 2026 | $880M | +0.1% |
| Q4 2025 | $961M | +6.2% |
| Q3 2025 | $904M | -4.9% |
| Q2 2025 | $936M | -4.9% |
| Q1 2025 | $879M | -7.8% |
| Q4 2024 | $905M | -11% |
XRAY's revenue fell from its 2019 peak and has held roughly level since: $836M last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.4% | +29 points |
| Q2 2026 | 9.1% | +23 points |
| Q1 2026 | -4% | -11 points |
| Q4 2025 | -14% | +42 points |
| Q3 2025 | -24% | +25 points |
| Q2 2025 | -14% | -19 points |
| Q1 2025 | 7.2% | +2.8 points |
| Q4 2024 | -56% | -64 points |
XRAY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XRAY on cash flow, with more consistent year-over-year improvement.
XRAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $0 | -100% |
| Q2 2026 | $55M | +244% |
| Q1 2026 | -$12M | $0 |
| Q4 2025 | $60M | +67% |
| Q3 2025 | $40M | -59% |
| Q2 2025 | $16M | -90% |
| Q1 2025 | -$12M | -$3M |
| Q4 2024 | $36M | -70% |
XRAY still generates free cash flow, though less than at its 2019 peak: $103M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XRAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1.3M shares |
| 1 year | -0.2% | -300K shares |
| 3 years | -5.9% | -12.6M shares |
| 5 years | -9.7% | -21.3M shares |
| Available history | -11% | -25.2M shares |
XRAY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $100M |
| Q2 2024 | $150M |
| Q1 2024 | — |
| Q4 2023 | $150M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over XRAY on leverage, with a lower net debt burden relative to earnings.
XRAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.1x | High |
| Q2 2026 | 50.9x | High |
| Q3 2024 | 39.2x | High |
| Q2 2024 | 6.6x | High |
| Q1 2024 | 5.9x | High |
| Q4 2023 | 6.9x | High |
| Q3 2023 | 6.9x | High |
| Q2 2022 | 1.9x | Healthy |
XRAY's net debt is about 7.1 years of its operating earnings (EBITDA), up from 5.9 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XRAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 22.9 | Neutral |
XRAY's weekly RSI is 41 (neutral) and its Stochastic is 23 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XRAY PE vs Healthcare Sector
| Metric | XRAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XRAY has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over XRAY on trend strength, trading above more of its moving averages.
XRAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.14 | 1.1% above |
| 20 week MA | $10.7 | 14% below |
| 50 week MA | $11.3 | 18% below |
| 100 week MA | $13.2 | 30% below |
| 200 week MA | $22.7 | 59% below |
XRAY has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 59% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over XRAY on returns for 2026, with the stronger performance.
XRAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $56.8 | $51.8 | -8.8% |
| 2021 | $51.8 | $55.4 | +7% |
| 2022 | $55.4 | $31.8 | -43% |
| 2023 | $31.8 | $35.6 | +12% |
| 2024 | $35.6 | $18.9 | -47% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.24 | -20% |
XRAY has finished lower in four of the last six years. It's down 20% so far in 2026.